In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks that Jim Cramer discussed 6 months ago during his show on July 29, 2024 ...
Abbott Laboratories (ABT) Q4 CY2024 Highlights: Revenue: $10.97 billion vs analyst estimates of $11.02 billion (7.2% year-on-year growth, in line) Adjusted EPS: $1.34 vs analyst estimates of $1.34 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback